Categories
Alivus Life Sciences Limited — Updates, 14-05-2026: Press Release
14-05-2026 · 07:59 pm
Alivus Life Sciences posted strong FY26: Revenue 2551.8 Cr (+6.9% YoY), EBITDA 857.7 Cr (+19.6% YoY, 33.6% margin). PAT 564.5 Cr (+16.2% YoY). Targets high single-digit FY27 revenue growth with >30% margins. Building new R&D center.
No comments yet. Be the first to comment!